



1939
Johnson & Johnson establishes the Ortho Products Division

Dr. Philip Levine discovers the connection between the Rhesus factor and the incidence of Hemolytic Disease of the Newborn (HDN)

1968
RhoGAM® Brand, the first life saving treatment for HDN is introduced to the market

1974
The Ortho Diagnostics Division becomes a full and separate member of the Johnson & Johnson Family of Companies (later named Ortho Diagnostic Systems)

1978
Eastman Kodak Clinical Diagnostics Division introduces patented thin-film dry-slide technology for laboratories

1986
Therakos is incorporated to develop photopheresis therapy

1989
Ortho Diagnostic Systems introduces ORTHO HCV ELISA Test System, the first test for the detection of antibodies to hepatitis C

1990
Ortho Diagnostic Systems acquires Du Pont blood screening business

1993
Ortho Diagnostic Systems launches the ORTHO BioVue® System for blood typing and compatibility testing outside of North America

1994
Johnson & Johnson acquires the Clinical Diagnostics Division of Eastman Kodak. The company is named Johnson & Johnson Clinical Diagnostics

1996
Johnson & Johnson Clinical Diagnostics introduces the first test kit to screen blood for antigens to HIV-1, the virus responsible for the vast majority of AIDS cases in the U.S.

1997
Johnson & Johnson Clinical Diagnostics and Ortho Diagnostic Systems merge. The new division is named Ortho Clinical Diagnostics (OCD)

OCD launches the VITROS® ECI Immunodiagnostic System

OCD introduces the ORTHO AutoVue® System, the first fully automated, random access instrument for blood typing and compatibility testing in Europe

1999
OCD introduces the ORTHO Summit™ System, the first fully automated blood and plasma screening system in the U.S.

2000
Advanced Cellular and Diagnostic Systems (now Veridex) is established to provide high-value diagnostics, monitoring and screening solutions for cancer

OCD launches first hepatitis test approved for use on a random access automated system

2002
OCD acquires Micro Typing Systems, the manufacturer of the ID-Micro Typing System™ (ID-MTS) Gel Test used to help ensure safe, effective blood transfusions in North America

2003
OCD launches ORTHO ProVue® Analyzer, the first fully automated blood banking system in North America

2004
Veridex launches the first CellSearch® Circulating Tumor Cell (CTC) Test to help physicians determine the prognosis of patients with metastatic breast cancer

OCD launches the VITROS® ECiQ Immunodiagnostic System

OCD launches the VITROS® 5,1 FS Chemistry System, a high-performance, high-capacity chemistry system

2005
OCD launches the VITROS® 350 Chemistry System, a compact chemistry system designed to be efficient, dependable and easy to use

2006
OCD launches the ORTHO® *T. cruzi* ELISA Test System, the first test to screen blood donors for Chagas, a tropical disease that affects 16-18 million people worldwide

2007
OCD launches the VITROS® Troponin I ES Assay, used along with other cardiac tests to help diagnose a heart attack and evaluate heart injury

Veridex launches the GeneSearch™ Breast Lymph Node (BLN) Assay and *TIME* magazine recognizes it as one of the top medical breakthroughs of the year

Veridex receives FDA clearance for the CellSearch® System, used as an aid in the monitoring of metastatic colorectal cancer

2008
Therakos receives a CE Mark in Europe for the CELLEX™ Photopheresis System

Johnson & Johnson Nordic AB acquires Amic, bringing unique Point-of-Care diagnostic technologies to the OCD franchise

The Cleveland Clinic recognizes the technology used in the CellSearch® System to measure CTCs as the top medical innovation for 2009

Veridex receives FDA clearance for the CellSearch® System, used as an aid in the monitoring of metastatic prostate cancer

Veridex completes acquisition of Immunicon Corporation, including all assets related to the CellSearch® System

OCD receives FDA approval of the VITROS® Anti-HIV 1+2 assay, which can be run in under 50 minutes on the VITROS® ECi/ECiQ Immunodiagnostic System

2009
OCD launches the VITROS® 5600 Integrated System and the VITROS® 3600 Immunodiagnostic System

Therakos receives Health Canada clearance for the CELLEX™ Photopheresis System

Therakos receives FDA approval for the CELLEX™ Photopheresis System

CellSearch™ CTC Test wins Prix Galien Award for Best Medical Technology